CN101808996A - 烟酰胺衍生物、它们的制备和它们的在治疗学中的应用 - Google Patents

烟酰胺衍生物、它们的制备和它们的在治疗学中的应用 Download PDF

Info

Publication number
CN101808996A
CN101808996A CN200880109332A CN200880109332A CN101808996A CN 101808996 A CN101808996 A CN 101808996A CN 200880109332 A CN200880109332 A CN 200880109332A CN 200880109332 A CN200880109332 A CN 200880109332A CN 101808996 A CN101808996 A CN 101808996A
Authority
CN
China
Prior art keywords
methyl
phenyl
pyridin
niacinamide
urea groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880109332A
Other languages
English (en)
Chinese (zh)
Inventor
J·阿里冈
C·伯恩哈特
M·鲍亚布拉
P·卡塞拉斯
R·科姆贝特
S·杰厄姆
S·希拉雷特
P·弗拉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CN101808996A publication Critical patent/CN101808996A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN200880109332A 2007-09-28 2008-09-26 烟酰胺衍生物、它们的制备和它们的在治疗学中的应用 Pending CN101808996A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0706799 2007-09-28
FR0706799A FR2921657A1 (fr) 2007-09-28 2007-09-28 Derives de nicotinamide, leur preparation et leur application en therapeutique
PCT/FR2008/001338 WO2009074749A2 (fr) 2007-09-28 2008-09-26 Dérives de nicotinamide. leur préparation et leur application en thérapeutique

Publications (1)

Publication Number Publication Date
CN101808996A true CN101808996A (zh) 2010-08-18

Family

ID=39356668

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880109332A Pending CN101808996A (zh) 2007-09-28 2008-09-26 烟酰胺衍生物、它们的制备和它们的在治疗学中的应用

Country Status (19)

Country Link
US (1) US20100222319A1 (https=)
EP (1) EP2205566A2 (https=)
JP (1) JP2010540504A (https=)
KR (1) KR20100065165A (https=)
CN (1) CN101808996A (https=)
AR (1) AR066171A1 (https=)
AU (1) AU2008334457A1 (https=)
BR (1) BRPI0817973A2 (https=)
CA (1) CA2700559A1 (https=)
CL (1) CL2008002893A1 (https=)
FR (1) FR2921657A1 (https=)
IL (1) IL204663A0 (https=)
MX (1) MX2010003445A (https=)
PA (1) PA8797301A1 (https=)
PE (1) PE20091033A1 (https=)
RU (1) RU2010116765A (https=)
TW (1) TW200918056A (https=)
UY (1) UY31367A1 (https=)
WO (1) WO2009074749A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103958479A (zh) * 2011-09-26 2014-07-30 赛诺菲 吡唑并喹啉酮衍生物、其制备和其治疗用途
CN110396065A (zh) * 2019-06-25 2019-11-01 南京普锐达医药科技有限公司 一种2,4-二氯-5-嘧啶甲酰氯的合成方法

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102775396B (zh) 2005-11-08 2014-10-08 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的杂环调控剂
CN104447716A (zh) 2007-05-09 2015-03-25 沃泰克斯药物股份有限公司 Cftr调节剂
MX365732B (es) 2007-12-07 2019-06-12 Vertex Pharma Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos.
EP3683218B1 (en) 2007-12-07 2024-09-18 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
NZ720282A (en) 2008-02-28 2017-12-22 Vertex Pharma Heteroaryl derivatives as cftr modulators
FR2943675A1 (fr) * 2009-03-24 2010-10-01 Sanofi Aventis Composes anticancereux, leur preparation et leur application en therapeutique
FR2943670B1 (fr) * 2009-03-24 2011-05-06 Sanofi Aventis Derives anticancereux,leur preparation et leur application en therapeutique
FR2943669B1 (fr) * 2009-03-24 2011-05-06 Sanofi Aventis Derives de nicotinamide,leur preparation et leur application en therapeutique
EP2440204B1 (en) * 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
AU2011223790A1 (en) * 2010-03-01 2012-08-30 Myrexis, Inc. Compounds and therapeutic uses thereof
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与
US8827372B2 (en) 2010-07-07 2014-09-09 Frontis Corp. Blowing system
FR2965263A1 (fr) * 2010-09-24 2012-03-30 Sanofi Aventis Derives de thienopyridine nicotinamide, leur preparation et leur application en therapeutique
US9169246B2 (en) 2011-09-26 2015-10-27 Sanofi Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
CN103012397B (zh) * 2011-09-26 2017-03-01 赛诺菲 吡唑并喹啉酮衍生物、其制备方法及其治疗用途
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
AU2014349010C1 (en) 2013-11-12 2020-08-06 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
CN103804270B (zh) * 2014-01-23 2016-06-22 中国药科大学 5-(4-甲脒基苄氧基)色氨酸衍生物、其制法及应用
RU2691136C2 (ru) 2014-11-18 2019-06-11 Вертекс Фармасьютикалз Инкорпорейтед Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии
JP7092356B2 (ja) * 2016-06-22 2022-06-28 フーダン ユニヴァーシティ ビアリール尿素誘導体またはそれらの塩、およびそれらの調製方法および使用
CN107522641B (zh) * 2016-06-22 2020-05-05 复旦大学 联芳基脲类衍生物或其盐及其制备方法和用途
KR102831570B1 (ko) 2018-05-04 2025-07-10 레미디 플랜, 인크. 암 줄기 세포를 표적화하는 암 치료
AU2020378067A1 (en) * 2019-11-06 2022-05-26 Remedy Plan, Inc. Cancer treatments targeting cancer stem cells
WO2021219513A1 (en) 2020-04-28 2021-11-04 Basf Se Pesticidal compounds
JP2024518089A (ja) * 2021-05-13 2024-04-24 リメディー プラン，インコーポレーテッド Ｎａｍｐｔ阻害剤とその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4301110A1 (de) * 1993-01-18 1994-07-21 Bayer Ag Verfahren zur Herstellung von 2-Amino-5-aminomethyl-pyridin
CZ20012185A3 (cs) * 1998-12-16 2001-10-17 Bayer Aktiengesellschaft Nové bifenylové sloučeniny a sloučeniny analogické bifenylovým sloučeninám, způsob jejich přípravy, farmaceutické prostředky a pouľití těchto sloučenin a prostředků jako antagonistů integrinu
DE10063008A1 (de) * 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
US20040067985A1 (en) * 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
JP2007515400A (ja) * 2003-11-28 2007-06-14 ノバルティス アクチエンゲゼルシャフト タンパク質キナーゼ依存性疾患の処置におけるジアリール尿素誘導体
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103958479A (zh) * 2011-09-26 2014-07-30 赛诺菲 吡唑并喹啉酮衍生物、其制备和其治疗用途
CN103958479B (zh) * 2011-09-26 2017-06-13 赛诺菲 吡唑并喹啉酮衍生物、其制备和其治疗用途
CN110396065A (zh) * 2019-06-25 2019-11-01 南京普锐达医药科技有限公司 一种2,4-二氯-5-嘧啶甲酰氯的合成方法

Also Published As

Publication number Publication date
AU2008334457A1 (en) 2009-06-18
WO2009074749A2 (fr) 2009-06-18
WO2009074749A3 (fr) 2009-08-20
RU2010116765A (ru) 2011-11-27
PA8797301A1 (es) 2009-05-15
FR2921657A1 (fr) 2009-04-03
MX2010003445A (es) 2010-04-27
CA2700559A1 (fr) 2009-06-18
EP2205566A2 (fr) 2010-07-14
PE20091033A1 (es) 2009-08-17
US20100222319A1 (en) 2010-09-02
UY31367A1 (es) 2009-04-30
CL2008002893A1 (es) 2009-10-16
KR20100065165A (ko) 2010-06-15
IL204663A0 (en) 2010-11-30
AR066171A1 (es) 2009-07-29
JP2010540504A (ja) 2010-12-24
BRPI0817973A2 (pt) 2019-04-09
TW200918056A (en) 2009-05-01

Similar Documents

Publication Publication Date Title
CN101808996A (zh) 烟酰胺衍生物、它们的制备和它们的在治疗学中的应用
CN104080774B (zh) 吡嗪甲酰胺化合物
JP4778959B2 (ja) キナーゼ阻害剤としての単環式複素環
CA2605854C (en) Novel pyridine derivative and pyrimidine derivative (3)
TWI221470B (en) Pyrimidine derivatives and pharmaceutical compositions containing the same
CN102459187B (zh) Janus激酶抑制化合物和方法
EP3405192B1 (en) Bruton's tyrosine kinase inhibitors
SG182400A1 (en) Voltage-gated sodium channel blockers
CN108137507A (zh) 基于mdm2的蛋白水解调节剂和相关的使用方法
AU2010277588A1 (en) Pyridine and pyrazine derivatives as protein kinase modulators
CN103270023A (zh) 作为用于治疗疾病诸如癌症的nampt 抑制剂的4-{[(吡啶-3-基-甲基)氨基羰基]氨基}苯-砜衍生物
CN106029661A (zh) 吡唑并[1,5-a]吡啶衍生物及其使用方法
CN108349981A (zh) 新型的吡唑并[3，4－d]嘧啶化合物或其盐
JP2005533011A (ja) ヒストンデアセチラーゼ阻害剤として有用なベンズアミド誘導体
WO2020119739A1 (zh) 2-氨基嘧啶类化合物及其应用
CN103298787A (zh) 3-(氨基芳基)-吡啶化合物
AU2005317870A1 (en) Pyridine carboxamide derivatives for use as anticancer agents
US20120053170A1 (en) Nicotinamide derivatives, preparation thereof, and therapeutic use thereof as anticancer drugs
KR20140049027A (ko) 치환된 헤테로사이클릭 아자 유도체
CA2840394A1 (en) Voltage-gated sodium channel blockers
ES2359836T3 (es) Heterociclos monociclicos como inhibidores de quinasa.
HK1145491A (zh) 烟酰胺衍生物、它们的制备和它们的在治疗学中的应用
JP2025503006A (ja) 新規ベンズイミダゾールピリジン誘導体
US20120053209A1 (en) Anticancer compounds, preparation thereof, and therapeutic use thereof
US20120094986A1 (en) Anticancer deriviatives, preparation thereof, and therapeutic use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1145491

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100818

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1145491

Country of ref document: HK